RxDoctor Payments Data

Alison Hansen, OD

Optometrist · Tulsa, OKNPI 1740298041

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 65.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $112 and has fallen 75.6% since, to $27 in 2025. That places this record below the midpoint for optometrist clinicians in OK, where the typical reported total is $560.

$402in general payments, 2019–2025

Across 20 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$264
  • Coopervision Inc.$51
  • Johnson & Johnson Vision Care, Inc.$27
  • Carl Zeiss Meditec AG$19
  • AbbVie$16
  • Sun Pharmaceutical Industries Inc.$15
  • plus $10 from 1 others

What the payments were for

  • Food & beverage$38295%
  • Gifts$195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$402 in reported general payments places this provider in the 40th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma →

Medicare billing

Part B allowed, 2024
$27,214
Medicare patients
176
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost36$299
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$242
Timolol Maleate12$144
Brimonidine Tartrate19$109

Paid to pharmacies, not to this prescriber.

Other optometrist in Tulsa

See the full list for Oklahoma →

Where these figures come from

Is this you, or does something look wrong? →